[Federal Register: June 16, 2004 (Volume 69, Number 115)]
[Notices]
[Page 33665-33666]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr16jn04-80]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By notice dated October 7, 2003, and published in the Federal
Register on October 29, 2003, (68 FR 61699), Guilford Pharmaceuticals,
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made
application by renewal to the Drug Enforcement Administration
[[Page 33666]]
for registration as a bulk manufacturer of Cocaine (9041), a basic
class of controlled substance listed in Schedule II.
The firm plans to manufacture a Schedule II cocaine derivative as a
final intermediate for the production of dopascan injection.
No comments or objections have been received. DEA has considered
the factors in title 21, United States Code, section 823(a) and
determined that the registration of Guilford Pharmaceuticals, Inc. to
manufacture the listed controlled substance is consistent with the
public interest at this time. DEA has investigated Guilford
Pharmaceuticals, Inc. to ensure that the company's registration is
consistent with the public interest. This investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant
Administrator, Office of Diversion Control, hereby orders that the
application submitted by the above firm for registration as a bulk
manufacturer of the basic class of controlled substance listed is
granted.
Dated: May 26, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 04-13537 Filed 6-15-04; 8:45 am]
BILLING CODE 4410-09-M